** Cryoport's CYRX.O shares jump 23.2% to $7
** CYRX provides supply chain solutions for life sciences companies
** Brokerage UBS upgrades CYRX's rating to "buy" from "neutral"
** Headwinds in CYRX's MVE subsidiary and broader biopharma market weakness have depressed sales, but these challenges are well understood, appear to be stabilizing, and provide an attractive entry point - UBS
** Expect Cryoport to achieve positive free cash flow by 2027, brokerage says
** Scaling cell and gene therapy service offerings provide a credible pathway to low-double-digit+ (~10+) mid-long term sales growth and positive free cash flow - UBS
** As of last close, CYRX had fallen ~27% YTD
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.